Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPN-443
- Development stage
- Unknown
- Lead developer
- Supernus Pharmaceuticals
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
SPN-443 is a novel stimulant drug candidate developed by Supernus Pharmaceuticals for the treatment of central nervous system (CNS) disorders, with a primary focus on attention-deficit hyperactivity disorder (ADHD). It is classified as a new molecular entity and has been evaluated in Phase I clinical trials, where two oral formulations demonstrated adequate bioavailability and were well tolerated in healthy adults. The precise mechanism of action for SPN-443 has not been publicly disclosed as of June 2025. The company expects to announce the lead indication for this product candidate by the end of 2025[1][7][8].
- Other names
- SPN 443SPN443SPN-443
Beyond the preview
Go deeper on SPN-443.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPN-443.